TY - JOUR T1 - Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. AU - Tanguy-Schmidt,Aline, AU - Rousselot,Philippe, AU - Chalandon,Yves, AU - Cayuela,Jean-Michel, AU - Hayette,Sandrine, AU - Vekemans,Marie-Christiane, AU - Escoffre,Martine, AU - Huguet,Françoise, AU - Réa,Delphine, AU - Delannoy,André, AU - Cahn,Jean-Yves, AU - Vernant,Jean-Paul, AU - Ifrah,Norbert, AU - Dombret,Hervé, AU - Thomas,Xavier, Y1 - 2012/09/06/ PY - 2012/04/16/received PY - 2012/08/29/accepted PY - 2012/9/11/entrez PY - 2012/9/11/pubmed PY - 2013/6/8/medline SP - 150 EP - 5 JF - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation JO - Biol Blood Marrow Transplant VL - 19 IS - 1 N2 - We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P = .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response). SN - 1523-6536 UR - https://www.unboundmedicine.com/medline/citation/22960387/Long_term_follow_up_of_the_imatinib_GRAAPH_2003_study_in_newly_diagnosed_patients_with_de_novo_Philadelphia_chromosome_positive_acute_lymphoblastic_leukemia:_a_GRAALL_study_ DB - PRIME DP - Unbound Medicine ER -